Evommune, Inc. (EVMN)

PHARMACEUTICAL PREPARATIONS

Evommune, Inc. (EVMN) is listed on the New York Stock Exchange, where it has traded since November 6, 2025.

Listed On
the New York Stock Exchange
Listed Since
November 6, 2025
Employees
48
Market Cap
$308M

About Evommune, Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 101 institutions reported holding EVMN, with 34.6 million shares worth $462.5 million in aggregate. The largest reported holder was Eqt Fund Management S.a R.L, with 5.3 million shares worth $70.3 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.

InstitutionSharesValueQuarter change
Eqt Fund Management S.a R.L5,288,313$70MAdded 7.28%
RA Capital Management,3,494,638$46MUnchanged
T. Rowe Price1,940,939$26MAdded 73.45%
Pivotal Bioventure Partners Investment Advisor1,926,943$26MUnchanged
JPMorgan Chase1,553,132$23MAdded 6.42%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is EVMN?

Evommune, Inc. (EVMN) is listed on the New York Stock Exchange, where it has traded since November 6, 2025.

Who are the largest institutional holders of EVMN?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of EVMN were Eqt Fund Management S.a R.L, RA Capital Management, and T. Rowe Price.

How many institutions own EVMN?

101 institutions reported a position in EVMN for the quarter ended June 30, 2026, worth $462.5 million in total.

Did institutions buy or sell EVMN last quarter?

Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for EVMN.

Every reported institutional holder, plus insider and congressional trades in EVMN, on SentiSense.